QUELL THERAPEUTICS LIMITED

11890040
Active United Kingdom

Research and experimental development on biotechnology

146 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Q

QUELL THERAPEUTICS LIMITED

11890040

Research and experimental development on biotechnology

Founded 19 Mar 2019 Active United Kingdom 146 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 9 Jun 2026 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 15 May 2026 Next due 12 May 2027 11 months remaining
Net assets £79M £4M 2024 year on year
Total assets £91M £37M 2024 year on year
Total Liabilities £12M £33M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for QUELL THERAPEUTICS LIMITED (11890040), an active life sciences and medical technology company based in United Kingdom. Incorporated 19 Mar 2019. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2019–2024)

Cash in Bank

£60.47M

Decreased by £46.25M (-43%)

Net Assets

£78.59M

Decreased by £3.85M (-5%)

Total Liabilities

£12.18M

Decreased by £32.94M (-73%)

Turnover

£43.83M

Increased by £34.67M (+378%)

Employees

146

Increased by 8 (+6%)

Debt Ratio

13%

Decreased by 22 (-63%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 4

Investors (12)

Investor NameInvestor SinceParticipating Rounds
Investor 10May 2019Series B, Series A
Investor 12May 2019Series A
Investor 11Feb 2021Series A

Share Capital

Share Capital

Share allotments and capital structure

11 Allotments 83,255,061 Shares £87.89m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
27 Mar 20263,233,307£32.333£0
27 Mar 202612,694,892£126.949£0
27 Mar 20263,802,812£38.028£0
2 Jun 202312,025,012£19.88m£1.654
25 Mar 202223,232,316£43.91m£1.89

Officers

Officers

1 active 2 resigned
Status
Beshar, Luke MatthewDirectorAmericanUnited States6824 Jul 2024Active

Shareholders

Shareholders (257)

Syncona Portfolio Limited
27.2%
45,171,429
Jeito S.l.p
9.5%
15,873,015

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Syncona Limited

British Channel Islands

Active
Notified 29 Mar 2019
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Syncona Portfolio Limited

Ceased 29 Mar 2019

Ceased

Group Structure

Group Structure

QUELL THERAPEUTICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

1 leasehold 1 total
AddressTenurePrice PaidDate Added
Translation And Innovation Hub, White City Campus, 80 Wood Lane, London (W12 0BZ) HAMMERSMITH AND FULHAM
Leasehold-27 Aug 2024
Translation And Innovation Hub, White City Campus, 80 Wood Lane, London (W12 0BZ)
Leasehold
Added 27 Aug 2024
District HAMMERSMITH AND FULHAM

Documents

Company Filings

DateCategoryDescriptionDocument
9 Jun 2026AccountsAnnual accounts made up to 31 Dec 2025
15 May 2026Confirmation StatementConfirmation statement made on 28 Apr 2026 with updates
13 May 2026OfficersChange to director Sir Robert Lechler on 2 Jun 2020
13 May 2026OfficersChange to director Mr Iain Mcgill on 1 Jan 2020
11 May 2026OfficersChange to director Luke Beshar on 24 Jul 2024
9 Jun 2026 Accounts

Annual accounts made up to 31 Dec 2025

15 May 2026 Confirmation Statement

Confirmation statement made on 28 Apr 2026 with updates

13 May 2026 Officers

Change to director Sir Robert Lechler on 2 Jun 2020

13 May 2026 Officers

Change to director Mr Iain Mcgill on 1 Jan 2020

11 May 2026 Officers

Change to director Luke Beshar on 24 Jul 2024

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

5 days ago on 9 Jun 2026

Confirmation statement made on 28 Apr 2026 with updates

1 months ago on 15 May 2026

Change to director Sir Robert Lechler on 2 Jun 2020

1 months ago on 13 May 2026

Change to director Mr Iain Mcgill on 1 Jan 2020

1 months ago on 13 May 2026

Change to director Luke Beshar on 24 Jul 2024

1 months ago on 11 May 2026